TOKYO--(BUSINESS WIRE)--NTT Corporation (NTT) and the National Center for Neurology and Psychiatry (NCNP) have entered into a partnership agreement to develop “Brain Bio-Digital Twin” technology. The collaboration will focus on applying this groundbreaking technology to detect and prevent dementia, depression and other mental illnesses.

东京-（商业线）-NTT公司（NTT）和国家神经病学和精神病学中心（NCNP）已经签订了合作协议，以开发“脑生物数字双胞胎”技术。合作将集中于应用这项开创性技术来检测和预防痴呆，抑郁症和其他精神疾病。

NTT and NCNP will initially focus on practical applications of this technology that eliminate the need for invasive and costly testing of various brain diseases..

NTT和NCNP最初将专注于该技术的实际应用，从而消除了对各种脑部疾病进行侵入性和昂贵测试的需要。。

By implementing NTT’s Artificial Intelligence (AI) and Machine Learning (ML) technologies, the Brain-Bio Digital Twin technology has the potential to truly personalise medicine, helping to prevent medical errors and accelerate drug trials.

通过实施NTT的人工智能（AI）和机器学习（ML）技术，Brain Bio-Digital Twin技术具有真正个性化医疗的潜力，有助于预防医疗错误并加速药物试验。

The number of people diagnosed with dementia and depression is growing every year. A Japanese government study found that in 2025, approximately 6.75 million people over the age of 65 in the country will have dementia.[1] In addition, the percentage of people diagnosed with depression in Japan has more than doubled since before the pandemic.[2] These conditions are challenging to address because of the lack of systematic medicines and treatment methods, the need for complex and highly invasive testing and the psychological and economic burden on patients..

被诊断患有痴呆症和抑郁症的人数每年都在增长。日本政府的一项研究发现，到2025年，该国约有675万65岁以上的人患有痴呆症。[1] 此外，自大流行之前以来，日本被诊断患有抑郁症的人数比例增加了一倍多。[2] 由于缺乏系统的药物和治疗方法，需要复杂而高度侵入性的检测以及患者的心理和经济负担，这些条件难以解决。。

NCNP, a board member of Japan Health Research Promotion Bureau, aims to overcome these challenges and achieve high-quality medical care, including personalised medicine, through the concept of the Brain Bio-Digital Twin (Figure 1). Specifically, the organisation is building a library platform that aggregates and systematically organises vast amounts of data on mental and nervous system diseases that have been acquired through clinical and research activities.

NCNP是日本卫生研究促进局的董事会成员，旨在通过脑生物数字双胞胎的概念克服这些挑战，实现高质量的医疗保健，包括个性化医疗（图1）。具体而言，该组织正在建立一个图书馆平台，汇集和系统地组织通过临床和研究活动获得的大量精神和神经系统疾病数据。

Once the data is collected and analysed, it can be used to model disease states using AI and ML and to develop an AI brain simulator that predicts brain states and functions of disease states..

一旦收集和分析数据，它就可以用于使用AI和ML对疾病状态进行建模，并开发AI脑模拟器，预测疾病状态的大脑状态和功能。。

In November 2020, NTT proposed the concept of Bio-Digital Twin, which allows users to map not only the brain but also the body and psychology as detailed digital data, to understand the current state of a person’s physical and mental conditions.[3] In addition to its experience in conducting research and development of a bio-digital twin for the mind and body, including the heart, NTT can leverage high-level AI and ML processing technology that enables NTT to accelerate research on Brain Bio-Digital Twin and make a significant contribution to the early development of these technologies.

2020年11月，NTT提出了生物数字双胞胎的概念，它允许用户不仅将大脑，而且将身体和心理学作为详细的数字数据进行映射，以了解一个人的身心状况的现状。[3] 除了为包括心脏在内的身心进行生物数字双胞胎研究和开发的经验之外，NTT还可以利用高级AI和ML处理技术，使NTT能够加速对大脑生物数字双胞胎的研究，为这些技术的早期发展做出重大贡献。

In addition, NTT will also build an ecosystem with business partners for commercialization and promotion..

此外，NTT还将与商业合作伙伴建立一个生态系统，以实现商业化和推广。。

As part of this partnership, NCNP will provide image data such as PET (Positron Emission Tomography) and bio samples (Blood, cerebrospinal fluid, tissue samples, genetic information, etc.), which are particularly useful for analysing cranial nerve diseases. NCNP will also provide medical interpretation of the underlying relationship between the results obtained by AI and ML processing and pathology, and necessary clinical implementation..

作为该合作伙伴关系的一部分，NCNP将提供图像数据，如PET（正电子发射断层扫描）和生物样本（血液，脑脊液，组织样本，遗传信息等），这些数据对分析颅神经疾病特别有用。NCNP还将提供AI和ML处理和病理学结果之间潜在关系的医学解释，以及必要的临床实施。。

The Brain Bio-Digital Twin incorporates various types of body data obtained through medical examinations into a computer as digital data and enables the creation of detailed maps and biological models through digital twin computing technology. The practical application of the Brain Bio-Digital Twin will enable the 'twin' to be used for testing, rather than the patient's own brain and nerves..

Brain Bio-Digital Twin将通过医学检查获得的各种类型的身体数据作为数字数据整合到计算机中，并通过数字双胞胎计算技术创建详细的地图和生物模型。大脑生物数字双胞胎的实际应用将使“双胞胎”能够用于测试，而不是患者自己的大脑和神经。。

The following effects can be expected from the practical application of the Brain Bio-Digital Twin.

脑生物数字双胞胎的实际应用可以预期以下效果。

Reduce the physical and mental burden of patients by eliminating the need for invasive and complex tests

通过消除对侵入性和复杂测试的需求来减轻患者的身心负担

Reduce patient’s cost burden by enabling simplified testing

通过简化测试减轻患者的成本负担

Conduct tests and treatments in small hospitals through data sharing of large testing equipment

通过大型测试设备的数据共享在小型医院进行测试和治疗

Premedication prediction of the presence and severity of side effects

术前预测副作用的存在和严重程度

Improve clinical efficacy by accelerating approval of medicines (supporting clinical trials)

通过加速药物批准（支持临床试验）提高临床疗效

Prediction of risk and early detection and prevention of disease by advanced analysis of clinical findings

通过临床发现的高级分析预测风险以及疾病的早期发现和预防

Systematic establishment of medicines and treatment methods through data collection, reproduction, and analysis of a wide variety of disease states

通过数据收集，复制和各种疾病状态分析系统建立药物和治疗方法

By bringing together accumulated data and knowledge, NCNP and NTT will begin to build a platform for processing Brain Bio-Digital Twin in FY 2024. In the next three years, the organisations plan to model several brain and nervous system functions and diseases. Subsequently, the organisations will cooperate with pharmaceutical regulations on pressing issues that require the development of effective therapeutic medicines and aim to create a practical system for the early detection and prevention of diseases; for example, accurately predicting an individual's risk for severe side effects before taking medications..

通过汇集积累的数据和知识，NCNP和NTT将于2024财年开始建立处理大脑生物数字双胞胎的平台。在接下来的三年中，这些组织计划模拟几种大脑和神经系统功能和疾病。随后，这些组织将与药品法规合作，处理需要开发有效治疗药物的紧迫问题，旨在建立一个早期发现和预防疾病的实用体系；例如，在服药前准确预测个体发生严重副作用的风险。。

References:

参考文献：

[1] Cabinet Office: Annual Report on the Aging Society: 2017 (Summary)

[1] 内阁厅：老龄化协会年度报告：2017（摘要）

https://www8.cao.go.jp/kourei/english/annualreport/2017/2017pdf_e.html

https://www8.cao.go.jp/kourei/english/annualreport/2017/2017pdf_e.html

[2] OECD: A New Benchmark for Mental Health Systems

[2] 经合组织：精神卫生系统的新基准

https://www.oecd.org/health/a-new-benchmark-for-mental-health-systems-4ed890f6-en.htm

https://www.oecd.org/health/a-new-benchmark-for-mental-health-systems-4ed890f6-en.htm

[3] NTT R&D: Bio-Digital Twin Technology and Medical Business

[3] NTT研发：生物数字孪生技术和医疗业务

https://www.rd.ntt/research/JN202301_20618.html

https://www.rd.ntt/research/JN202301_20618.html

About NTT

关于NTT

NTT contributes to a sustainable society through the power of innovation. We are a leading global technology company providing services to consumers and business as a mobile operator, infrastructure, networks, applications, and consulting provider. Our offerings include digital business consulting, managed application services, workplace and cloud solutions, data center and edge computing, all supported by our deep global industry expertise.

NTT通过创新力量为可持续社会做出贡献。我们是一家领先的全球技术公司，为移动运营商，基础设施，网络，应用程序和咨询提供商提供服务给消费者和企业。我们的产品包括数字业务咨询，托管应用程序服务，工作场所和云解决方案，数据中心和边缘计算，所有这些都得到了我们深入的全球行业专业知识的支持。

We are over $100B in revenue and 330,000 employees, with $3.6B in annual R&D investments. Our operations span across 80+ countries and regions, allowing us to serve clients in over 190 of them. We serve over 75% of Fortune Global 100 companies, thousands of other enterprise and government clients and millions of consumers..

我们的收入超过1亿美元，员工33万，年度研发投资为36亿美元。我们的运营跨越80多个国家和地区，使我们能够为其中190多个客户提供服务。我们为“财富”全球100家公司，数千家其他企业和政府客户以及数百万消费者提供服务。。

About NCNP

关于NCNP

The National Center of Neurology and Psychiatry (NCNP), located in the suburb of Tokyo, was established in 1986, as one of the six national centers of Japan. Our activities are characterized by close affiliation of two major Institutes (National Institute of Neuroscience and National Institute of Mental Health) and National Center Hospital of Neurology and Psychiatry.

位于东京郊区的国家神经病学和精神病学中心（NCNP）成立于1986年，是日本六个国家中心之一。我们的活动的特点是与两个主要研究所（国家神经科学研究所和国家心理健康研究所）和国家神经病学和精神病学中心医院密切相关。

This effort is catalyzed by the Translational Medical Center, Integrative Brain Imaging Center, Center for Cognitive Behavior Therapy and Research and other facilities. We contribute to human health and welfare. It offers high level medicine for patients with mental, nervous, muscular, and developmental disorders and aims to improve their quality of life (QOL).

这项工作由转化医学中心，综合脑成像中心，认知行为治疗和研究中心以及其他设施推动。我们为人类健康和福利做出贡献。它为患有精神，神经，肌肉和发育障碍的患者提供高水平的药物，旨在提高他们的生活质量（QOL）。

It promotes research on prevention and therapy of such disorders and produces highly qualified medical and health care professionals..

它促进了对这些疾病的预防和治疗的研究，并培养出高素质的医疗保健专业人员。。